Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Here are the Stocktwits Top 25 Lists for this week:

📈 Momentum Movers

This week’s board mixed fresh deal momentum, AI infrastructure, and one biotech data setup.

$ERAS ( ▼ 0.94% ) : Erasca, jumped 14 spots to #6: This week’s top dawg slipped -0.9% but held a +327% YTD gain. Erasca will discuss its cancer pipeline at Morgan Stanley on Sept. 15, with updated ERAS-0015 trial data due in November. Risk: The thesis still rests on early-stage clinical results.

$REAX ( ▲ 9.44% ) : Real REMAX Group, new at #1: Shares climbed +9.4% after Real closed its $880M RE/MAX combination and B. Riley raised its post-consolidation target to $65. Risk: The combined company must absorb RE/MAX and service a new $550M term loan.

$MXL ( ▲ 7.54% ) : MaxLinear, climbed five spots to #5: The chipmaker gained +7.5% as management took its AI storage and data-center connectivity pitch to two investor conferences. Risk: Arbitration over the terminated Silicon Motion merger still carries potential damages.

$BAND ( ▲ 10.17% ) : Bandwidth, slipped four spots to #13: The cloud communications stock jumped +10.2%, but faster names pushed it down the board. Voice AI demand and recent investor meetings kept the growth pitch moving. Risk: Its $275M convertible-note sale created another potential source of dilution.

$KOS ( ▲ 2.72% ) : Kosmos Energy, climbed two spots to #19: Shares gained +2.7% as crude broke above $100 and Middle East attacks threatened more supply. Risk: Kosmos lowered its 2026 production range after selling assets, leaving the rally increasingly dependent on oil prices.

Next week’s swing factor: The Fed’s Sept. 16 rate decision will hit the board’s real estate, biotech, and growth names at once.

Want to see some change? Email me, Kevin Travers, with feedback, and follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋